Kolexia
Emile George Oncologie médicale
Emile George
Oncologie médicale
Centre François-Baclesse
Caen, France
100 Activités
475 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Métastase tumorale Hypertension artérielle Cellules tumorales circulantes Récidive tumorale locale Tumeurs du sein triple-négatives Carcinomes Obésité

Collaborateurs

Voir plus
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Hrab Ioana
Hrab Ioana
Centre François-Baclesse, Caen, France
Segura-Djezzar Carine
Segura-Djezzar Carine
Centre François-Baclesse, Caen, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Novartis
14 collaboration(s)
Dernière en 2023
AstraZeneca
9 collaboration(s)
Dernière en 2023
A+A
6 collaboration(s)
Dernière en 2023
B3TSI
6 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
ELAINEIII: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Essai Clinique (Sermonix Pharmaceuticals Inc.)   07 mars 2024
ETIC-LM: Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients With Leptomeningeal Metastases
Essai Clinique (Seagen)   02 février 2024
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
European journal of cancer (Oxford, England : 1990)   10 novembre 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 novembre 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
The oncologist   11 octobre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
BMC cancer   19 septembre 2023
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
BMC cancer   09 août 2023
WEBAPPAC: Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
Essai Clinique (Centre François-Baclesse)   31 juillet 2023